Circio Holding ASA
CRNA.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.06B
Close$
Share Statistics
| Market cap | $3.06 Billion |
|---|---|
| Enterprise Value | $3.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.43 |
| Beta | -1.11 |
| Outstanding Shares | 209,917,000 |
Return
| Return on Equity | -16870.62% |
|---|---|
| Return on Assets | -431.12% |
| Return on Invested Capital | -817.24% |
Valuation & Multiples
| P/E Ratio | -28.83 |
|---|---|
| PEG | -2.36 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 305.92 |
| Enterprise Value to EBIT | -6.24 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 24.72 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Circio Holding ASA
10 employees
CEO: Erik Digman Wiklund Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at speci...